Page 45 - Haematologica-5

Safety and efficacy of plerixafor in SCD patients
uals with sickle cell disease: time for a mora-
torium? Cytotherapy. 2009;11(4):464-471.
6. Petit I, Szyper-Kravitz M, Nagler A, et al. G- CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-reg- ulating CXCR4. Nat Immunol. 2002;3(7):
687-694.
7. Cella G, Marchetti M, Vignoli A, et al. Blood
oxidative status and selectins plasma levels in healthy donors receiving granulocyte- colony stimulating factor. Leukemia. 2006;20(8):1430-1434.
8. de Haas M, Kerst JM, van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analy- sis of the immediate activating effects on cir- culating neutrophils. Blood. 1994;84(11): 3885-3894.
9. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulo- cyte colony-stimulating factor. Blood. 1999;93(8):2506-2514.
10. Spiel AO, Bartko J, Schwameis M, et al. Increased platelet aggregation and in vivo platelet activation after granulocyte colony- stimulating factor administration. A ran- domised controlled trial. Thromb Haemost. 2011;105(4):655-662.
11. Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez- Navarro F. Induction of a hypercoagulability state and endothelial cell activation by gran- ulocyte colony-stimulating factor in periph- eral blood stem cell donors. J Hematother Stem Cell Res. 2002;11(4):675-681.
12. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801- 809.
13. Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129 (19):2680-2692.
14. Choi E, Branch C, Cui MH, et al. No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. Blood Cells Mol Dis. 2016;57:67-70.
15. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. 1997;34(3 Suppl 3):15-21.
16. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell dis- ease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2):643-649.
17. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and mor- bidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
18. Litos M, Sarris I, Bewley S, Seed P, Okpala I, Oteng-Ntim E. White blood cell count as a predictor of the severity of sickle cell disease during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007;133(2):169-172.
19. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
20. Pantin J, Purev E, Tian X, et al. Effect of high- dose plerixafor on CD34(+) cell mobiliza- tion in healthy stem cell donors: results of a
randomized crossover trial. Haematologica.
2017;102(3):600-609.
21. Lamming CE, Augustin L, Blackstad M,
Lund TC, Hebbel RP, Verfaillie CM. Spontaneous circulation of myeloid-lym- phoid-initiating cells and SCID-repopulating cells in sickle cell crisis. J Clin Invest. 2003;111(6):811-819.
22. Croizat H, Ponchio L, Nicolini FE, Nagel RL, Eaves CJ. Primitive haematopoietic progenitors in the blood of patients with sickle cell disease appear to be endoge- nously mobilized. Br J Haematol. 2000;111 (2):491-497.
23. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-238.
24. Richard RE, Siritanaratkul N, Jonlin E, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell anemia. Blood Cells Mol Dis. 2005;35(3):384-388.
25. Manwani D, Chen G, Carullo V, et al. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sick- le cell pain crisis. Am J Hematol. 2015;90(5):381-385.
26. Jakubowski JA, Zhou C, Jurcevic S, et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014;133(2):190-195.
27. Canalli AA, Proenca RF, Franco-Penteado CF, et al. Participation of Mac-1, LFA-1 and VLA- 4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica. 2011;96(4):526-533.
28. Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One. 2014;9(7):e101301.
29. Nur E, van Beers EJ, Martina S, et al. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46(3):189-194.
30. de la Rubia J, Lorenzo JI, Torrabadella M, Marin P, Insunza A, Sanz MA. Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor. Haematologica. 2004;89(12):1530-1532.
31. Martino M, Gori M, Pitino A, et al. Basal CD34(+) Cell count predicts peripheral blood stem cell mobilization in healthy donors after administration of granulocyte colony-stimulating factor: a longitudinal, prospective, observational, single-center, cohort study. Biol Blood Marrow Transplant. 2017;23(7):1215-1220.
32. Kanter J, Walters MC, Hsieh MM, et al. Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood. 2017;128 (22):1176.
33. Uchida N, Fujita A, Hsieh MM, et al. Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: evi- dence from Rhesus and SCD patients. Hum Gene Ther Clin Dev. 2017;28(3):136-144.
34. Miller ST, Rey K, He J, et al. Massive acci-
dental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer. 2012;59(1):170-172.
35. Castro O, Nouraie M, Oneal P. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014;167(5):687-691.
36. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130(13):1597- 1599.
37. Drasar ER, Jiang J, Gardner K, et al. Leucocyte telomere length in patients with sickle cell disease. Br J Haematol. 2014;165 (5):725-727.
38. Baird JH, Minniti CP, Lee JM, et al. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycar- bamide. Br J Haematol. 2015;168(5):737-746.
39. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
40. Worel N, Frank N, Frech C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lympho- cyte subtypes. Transfusion. 2017;57(9): 2206-2215.
41. Javazon EH, Radhi M, Gangadharan B, Perry J, Archer DR. Hematopoietic stem cell func- tion in a murine model of sickle cell disease. Anemia. 2012;2012:387385.
42. Leonard A, Bonifacino A, Dominical VM, et al. Bone marrow characterization in sickle cell disease: inflammation and stress ery- thropoiesis lead to suboptimal CD34 recov- ery compared to normal volunteer bone marrow. Blood. 2017;130(Suppl 1):966.
43. Dallalio G, Brunson CY, Means RT, Jr. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Investig Med. 2007;55(2):69-74.
44. Colella MP, Santana BA, Conran N, et al. Telomere length correlates with disease severity and inflammation in sickle cell dis- ease. Rev Bras Hematol Hemoter. 2017;39 (2):140-145.
45. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8): 2728-2730.
46. Eidenschink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal lev- els of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months. Cytometry B Clin Cytom. 2012;82(1):18-25.
47. Hoggatt J, Singh P, Tate TA, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1- 2):191-204.e10.
48. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153(1):66-75.
49. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long- term multilineage engraftment. Science. 2011;333(6039):218-221.
haematologica | 2018; 103(5)
777